8-K: 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

89bio initiated a Phase 3 trial for MASH and is on track to begin another trial this quarter, while also reporting increased R&D spending and a net loss for the first quarter of 2024.

Summary

• 89bio announced its first quarter 2024 financial results and provided a corporate update.
• The company initiated the ENLIGHTEN-Fibrosis Phase 3 trial for non-cirrhotic MASH patients.
• They expect to initiate the ENLIGHTEN-Cirrhosis trial for MASH patients with compensated cirrhosis in the second quarter of 2024.
• The European Medicines Agency (EMA) granted Priority Medicines (PRIME) status to pegozafermin for MASH treatment.
• Data from the 48-week extension phase of the ENLIVEN Phase 2b trial will be presented at the European Association for the Study of the Liver Congress (EASL).
• Enrollment is progressing in the ENTRUST Phase 3 trial for severe hypertriglyceridemia (SHTG), with topline results expected in 2025.
• 89bio has a collaboration agreement with BiBo Biopharma for a pegozafermin production facility in China.
• The company appointed Martin Babler to its Board of Directors.
• As of March 31, 2024, 89bio had approximately $562.3 million in cash, cash equivalents, and marketable securities.
• Research and development expenses were $47.4 million for the quarter, compared to $22.3 million in the same period last year.
• General and administrative expenses were $9.8 million, up from $6.2 million year-over-year.
• The company reported a net loss of $51.7 million for the quarter, compared to a net loss of $28.8 million in the first quarter of 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and regulatory achievements, but tempered by the increased net loss and expenses.

Positives

• The initiation of the Phase 3 ENLIGHTEN-Fibrosis trial is a significant step forward for the company's MASH program.
• The expected initiation of the ENLIGHTEN-Cirrhosis trial in the second quarter of 2024 expands the scope of the MASH program.
• The PRIME status granted by the EMA for pegozafermin is a positive regulatory development.
• The collaboration with BiBo Biopharma secures a commercial supply of pegozafermin.
• The company has a strong cash position of $562.3 million, providing financial stability for ongoing operations.
• The presentation of the 48-week extension data from the ENLIVEN Phase 2b trial at EASL is a positive step for data dissemination.

Negatives

• The company reported a net loss of $51.7 million for the first quarter of 2024, which is an increase from the $28.8 million loss in the same period last year.
• Research and development expenses have significantly increased to $47.4 million, up from $22.3 million year-over-year.
• General and administrative expenses also increased to $9.8 million, compared to $6.2 million in the first quarter of 2023.

Risks

• The company is dependent on the success of its lead product candidate, pegozafermin.
• Clinical trial results may not be predictive of future outcomes.
• There is competition from other companies developing treatments for MASH and SHTG.
• The company's ability to raise additional capital is a risk.
• General economic, health, industrial, or political conditions could impact the company's operations.

Future Outlook

The company anticipates topline data from the ENTRUST Phase 3 trial in SHTG in 2025 and is focused on executing its Phase 3 trials for MASH. They are also preparing for potential commercialization of pegozafermin.

Management Comments

• Rohan Palekar, CEO of 89bio, stated that they are excited to have initiated ENLIGHTEN-Fibrosis and are on track to begin the ENLIGHTEN-Cirrhosis trial.
• The CEO believes that pegozafermin has the potential to be the leading therapy in treating advanced MASH patients with fibrosis.

Industry Context

The announcement is relevant to the broader pharmaceutical industry focused on developing treatments for liver and cardiometabolic diseases, particularly MASH and SHTG. The company's progress in Phase 3 trials and regulatory achievements position it as a key player in this space.

Comparison to Industry Standards

• The initiation of two Phase 3 trials for MASH is a significant step, comparable to other companies like Madrigal Pharmaceuticals and Viking Therapeutics who are also advancing MASH treatments.
• The PRIME designation from the EMA is a positive signal, similar to other companies receiving expedited regulatory pathways for their therapies.
• The company's cash position of $562.3 million is relatively strong compared to other clinical-stage biotechs, providing a runway for ongoing trials.
• The increase in R&D spending is consistent with the stage of development, as Phase 3 trials are typically more expensive than earlier phases.
• The net loss is also typical for a clinical-stage biotech company that is investing heavily in research and development.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the clinical trial progress.
• Employees may be impacted by the increased headcount and stock-based compensation.
• Patients with MASH and SHTG may benefit from the potential approval of pegozafermin.
• Suppliers and partners may see increased business opportunities due to the company's growth.

Next Steps

• Initiate the ENLIGHTEN-Cirrhosis trial in the second quarter of 2024.
• Present data from the 48-week extension phase of the ENLIVEN Phase 2b trial at the EASL Congress.
• Continue enrollment in the ENTRUST Phase 3 trial for SHTG.
• Host a key opinion leader webinar on pegozafermin on May 16, 2024.

Key Dates

Keywords

pegozafermin, MASH, NASH, SHTG, clinical trials, Phase 3, ENLIGHTEN, ENTRUST, EMA, PRIME, biopharmaceutical, FGF21